摘要
目的探讨吸入性糖皮质激素及白三烯受体拮抗剂对哮喘患者外周血白介素及肺功能的影响。方法收集我院2017年1—12月确诊为哮喘的50例患者作为研究对象,将其随机分为A组和B组。两组基础用药方案均为吸入布地奈德气雾剂,B组加用白三烯受体拮抗剂孟鲁司特钠口服。对比两组患者治疗前、治疗6个月血白介素及肺功能。结果治疗前,A组和B组治疗前血白介素及肺功能比较,差异无统计学意义(P> 0.05);A组患者治疗后IL-8高于对照组,IL-10低于B组,两组比较,差异具有统计学意义(P <0.05);A组患者治疗后肺功能指标中第1秒用力呼气容积、呼气峰流速,与B组比较,差异无统计学意义(P> 0.05);A组治疗后肺功能指标中用力肺活量及最大呼气中段流速低于B组,差异具有统计学意义(P <0.05)。结论吸入性糖皮质激素及白三烯受体拮抗剂可以减轻哮喘小儿体内炎症程度,改善肺功能。
Objective To investigate the effects of inhaled glucocorticoids and leukotriene receptor antagonists on peripheral blood interleukin and pulmonary function in asthmatic patients. Methods 50 patients with asthma diagnosed in our hospital from January to December 2017 were randomly divided into group A and group B. Both groups were given Budesonide aerosol inhalation. Group B was given montelukast sodium, a leukotriene receptor antagonist, orally. Blood interleukin and lung function were compared between the two groups before and 6 months after treatment. Results Before treatment, there was no significant difference in serum interleukin and lung function between group A and group B (P > 0.05). After treatment, IL-8 in group A was higher than that in group B, and IL- 10 was lower than that in group B. There was a significant difference between the two groups (P < 0.05). There was no significant difference in forced expiratory volume and peak expiratory flow rate between group A and group B (P > 0.05). After treatment, the forced vital capacity and maximum expiratory flow rate in group A were lower than those in group B, and the difference was statistically significant (P < 0.05). Conclusion Inhaled glucocorticoid and leukotriene receptor antagonist can alleviate inflammation and improve lung function in asthmatic children.
作者
李利雄
LI Lixiong(Department of Respiratory Medicine,Shanghai Jinshan District Integrated Chinese and Western Medicine Hospital,Shanghai 201501, China)
出处
《中国继续医学教育》
2019年第8期134-136,共3页
China Continuing Medical Education
关键词
糖皮质激素
白三烯受体拮抗剂
哮喘
白介素
肺功能
呼气峰流速
glucocorticoid
leukotriene receptor antagonist
asthma
interleukin
pulmonary function
peak expiratory flow rate
